Update on endocrine therapy for breast cancer

Clinical Cancer Research

Volumn 4, Issue 3, 1998, Pages 527-534

  Buzdar, Aman U ^a,b   Hortobagyi, Gabriel ^b  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b UNIVERSITY OF TEXAS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIANDROGEN; ANTIGESTAGEN; AROMATASE INHIBITOR; GONADORELIN AGONIST; TAMOXIFEN;

ANTINEOPLASTIC ACTIVITY; BREAST CANCER; BREAST METASTASIS; CANCER ADJUVANT THERAPY; CANCER HORMONE THERAPY; HUMAN; PRIORITY JOURNAL; REVIEW;

EID: 0031949639     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (53)

1. Beatson, G. T. On the treatment of inoperable cases of carcinoma of the mamma. Suggestion for a new method of treatment, with illustrative cases. Lancet, 2: 104-107, 1896.
2. Howell, A., Downey, S., and Anderson, E. New endocrine therapies for breast cancer. Eur. J. Cancer, 32A: 576-588, 1996.
3. Tonetti, D. A., and Jordan, V. C. Targeted anti-estrogens to treat and prevent diseases in women. Mol. Med. Today, 2: 218-223, 1996.
4. Sedlacek, S. M., and Horowitz, K. B. The role of progestins and progesterone receptors in the treatment of breast cancer. Steroids, 44: 467-484, 1984.
5. Beck, W. W. Obstetrics and gynecology, pp. 126. Baltimore, MD: Williams & Wilkins, 1989.
6. Goldhirsch, A., and Gelber, R. D. Endocrine therapies of breast cancer. Semin Oncol., 23: 494-505, 1996.
7. Jaiyesimi, I. A., Buzdar, A. U., Decker, D. A., and Hortobagyi, G. N. Use of tamoxifen for breast cancer: twenty-eight years later. J. Clin. Oncol., 13: 513-529, 1995.
8. Early Breast Cancer Trialists' Collaborative Group Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy: 133 randomized trials involving 31,000 recurrences and 24,000 deaths among 75,000 women. Lancet, 339: 1-15, 71-85, 1992.
9. Swedish Breast Cancer Cooperative Group Randomized trial of two versus five years of adjuvant tamoxifen for postmenopausal early stage breast cancer. J. Natl. Cancer Inst., 88: 1543-1549, 1996.
10. Fisher, B., Dignam, J., Bryant, J., DeCillis, A., Wickerham, D. L., Wolmark, N., Costantino, J., Redmond, C., Fisher, E. R., Bowman, D. M., Deschênes, L., Dimitrov, N. V., Margolese, R. G., Robidoux, A., Shibata, H., Terz, J., Paterson, A. I. G., Feldman, M. I., Farrar, W., Evans, J., and Lickley, H. L. Five versus more than five years of tamoxifen therapy for breast cancer patients with negative lymph nodes and estrogen receptor-positive tumors. J. Natl. Cancer Inst., 88: 1529-1542, 1996.
11. Tormey, D. C., Gray, R., and Falkson, H. C. Postchemotherapy adjuvant tamoxifen therapy beyond five years in patients with lymph node-positive breast cancer. J. Natl. Cancer Inst., 88: 1828-1833, 1996.
12. Nease, R. F., Jr., and Ross, J. M. The decision to enter a randomized trial of tamoxifen for the prevention of breast cancer in healthy women: an analysis of the tradeoffs. Am. J. Med., 99: 180-189, 1995.
13. Barakat, R. R. The effect of tamoxifen on the endometrium. Oncology, 9: 129-139, 1995.
14. Jordan, V. C., and Assikis, V. J. Endometrial carcinoma and tamoxifen: clearing up a controversy. Clin. Cancer Res., 1: 467-472, 1995.
15. Creasman, W. T. Endometrial cancer: incidence, prognostic factors, diagnosis, and treatment. Semin. Oncol., 24 (Suppl. 1): s1-140-s1-150, 1997.
16. Hayes, D. F., Van Zyl, J. A., Hacking, A., Goedhals, L., Bezwoda, W. R., Mailliard, J. A., Jones, S. E., Vogel, C. L., Berris, R. F., Shemano, I., and Schoenfelder, J. Randomized comparison of tamoxifen and two separate doses of toremifene in postmenopausal patients with metastatic breast cancer. J. Clin. Oncol., 13: 2556-2566, 1995.
17. Tomás, E., Kauppila, A., Blanco, G., Apaja-Sarkkinen, M., and Laatikainen, T. Comparison between the effects of tamoxifen and toremifene on the uterus in postmenopausal breast cancer patients. Gynecol. Oncol., 59: 261-266, 1995.
18. Vogel, C. L., Shemano, I., Schoenfelder, J., Gams, R. A., and Green, M. R. Multicenter phase II efficacy trial of toremifene in tamoxifen-refractory patients with advanced breast cancer. J. Clin. Oncol., 11: 345-350, 1993.
19. Stenbygaard, L. E., Herrstedt, J., Thomsen, J. F., Svendsen, K. R., Engelholm, S. A., and Dombernowsky, P. Toremifene and tamoxifen in advanced breast cancer - a double-blind cross-over trial. Breast Cancer Res. Treat., 25: 57-63, 1993.
20. Hasmann, M., Rattel, B., and Löser, R. Preclinical data for droloxifene. Cancer Lett., 84: 101-116, 1994.
21. Rauschning, W., and Pritchard, K. I. Droloxifene, a new antiestrogen: its role in metastatic breast cancer. Breast Cancer Res Treat., 31: 83-94, 1994.
22. Grese, T. A., Cho, S., Finley, D. R., Godfrey, A. G., Jones, C. D., Lugar, C. W. R., Martin, M. J., Matsumoto, K., Pennington, L. D., Winter, M. A., Adrian, M. D., Cole, H. W., Magee, D. E., Phillips, D. L., Rowley, E. R., Short, L. L., Glasebrook, A. L., and Bryant, H. U. Structure-activity relationships of selective estrogen receptor modulators: modifications to the 2-arylbenzothiophene core of raloxifene. J. Med. Chem., 40: 146-167, 1997.
23. Fuchs-Young, R., Glasebrook, A. L., Short, L. L., Draper, M. W., Rippy, M. K., Cole, H. W., Magee, D. E., Termine, J. D., and Bryant, H. U. Raloxifene is a tissue-selective agonist/antagonist that functions through the estrogen receptor. Ann. NY Acad. Sci., 761: 355-360, 1995.
24. Jordan, V. C. Alternate antiestrogens and approaches to the prevention of breast cancer. J. Cell Biochem. Suppl., 22: 51-57, 1995.
25. Wakeling, A. E., Dukes, M., and Bowler, J. A potent specific pure antiestrogen with clinical potential. Cancer Res., 51: 3867-3873, 1991.
26. DeFriend, D. J., Howell, A., Nicholson, R. I., Anderson, E., Dowsett, M., Mansel, R. E., Blarney, R. W., Bundred, N. J., Robertson, J. F., Saunders, C., Baum, M., Walton, P., Sutcliffe, F., and Wakeling, A. E. Investigation of a new pure antiestrogen (ICI 182780) in women with primary breast cancer. Cancer Res., 54: 408-414, 1994.
27. Howell, A., and Robertson, J. Response to a specific antioestrogen (ICI 182780) in tamoxifen-resistant breast cancer. Lancet, 345: 989-990, 1995.
28. Howell, A., DeFriend, D. J., Robertson, J. F. R., Blarney, R. W., Anderson, L., Anderson, E., Sutcliffe, F. A., and Walton, P. Clinical studies with the specific "pure" antioestrogen ICI 182780. Breast, 5: 192-195, 1996.
29. Davidson, N. E. Ovarian ablation as treatment for young women with breast cancer. Monogr. Natl. Cancer Inst., 16: 95-99, 1994.
30. Burger, C. W., Prinssen, H. M., and Kenemans, P. LHRH agonist treatment of breast cancer and gynecological malignancies: a review. Eur. J. Obstet. Gynecol. Reprod. Biol., 97: 27-33, 1996.
31. Harvey, H. A. Aromatase inhibitors in clinical practice: current status and a look to the future. Semin. Oncol., 23 (Suppl. 9):, 33-38, 1996.
32. Buzdar, A. U., Plourde, P. V., and Hortobagyi, N. Aromatase inhibitors in metastatic breast cancer. Semin. Oncol., 23 (Suppl. 9):, 28-32, 1996.
33. Goss, P. E., and Gwyn, K. M. E. H. Current perspectives on aromatase inhibitors in breast cancer. J. Clin. Oncol., 12: 2460-2470, 1994.
34. Dowsett, M., and Coombes, R. C. Second generation aromatase inhibitor - 4-hydroxyandrostenedione. Breast Cancer Res. Treat., 30: 81-87, 1994.
35. Plourde, P. V., Dyroff, M., and Dukes, M. Arimidex®: a potent and selective fourth-generation aromatase inhibitor. Breast Cancer Res. Treat., 30: 103-111, 1994.
36. Buzdar, A. U., Jonat, W., Howell, A., Jones, S. E., Blomqvist, C., Vogel, C. L., Eiermann, W., Wolter, J. M., Azab, M., Webster, A., Plourde, P. V., on behalf of the Arimidex Study Group. Anastrozole, a potent and selective aromatase inhibitor, versus megestrol acetate in postmenopausal women with advanced breast cancer: results of an overview analysis of two phase III trials. J. Clin. Oncol., 14: 2000-2011, 1996.
37. Buzdar, A., Jonat, W., Howell, A., Yin, H., and Lee, D., on behalf of the Arimidex International Study Group. Significant improved survival with Arimidex (anastrozole) versus megestrol acetate in postmenopausal advanced breast cancer: updated results of two randomized trials. Proc. Annu. Meet. Am. Soc. Clin. Oncol., 16: 156a, 1997.
38. Buzdar, A., Smith, R., Vogel, C. L., Bonomi, P., Keller, A. M., Favis, G., Mulagha, M., and Cooper, J., for the Multi-Institutional Trialist Study Group. Fadrozole HCL (CGS-16949A) versus megestrol acetate treatment of postmenopausal patients with metastatic breast carcinoma: results of two randomized double blind controlled multiinstitutional trials. Cancer (Phila.), 77: 2503-2513, 1996.
39. Demers, L. M., Lipton, A., Harvey, H. A., Hanagan, J., Mulagha, M., and Santen, R. J. The effects of long term fadrozole hydrochloride treatment in patients with advanced stage breast cancer. J. Steroid Biochem. Mol. Biol., 44: 683-685, 1993.
40. Dowsett, M., Smithers, D., Moore, J., Trunet, P. F., Coombes, R. C., Powles, T. J., Rubens, R., and Smith, I. E. Endocrine changes with the aromatase inhibitor fadrozole hydrochloride in breast cancer. Eur. J. Cancer, 30A: 1453-1458, 1994.
41. Thürlimann, B., Beretta, K., Bacchi, M., Castiglione-Gertsch, M., Goldhirsch, A., Jungi, W. F., Cavalli, F., Senn, H-J., and Löhnert, T., for the Swiss Group for Clinical Cancer Research (SAKK). First-line fadrozole (CGS 16949A) versus tamoxifen in postmenopausal women with advanced breast cancer. Ann. Oncol., 7: 471-479, 1996.
42. Dombernowsky, P., Smith, I., Falkson, G., Leonard, R., Panasci, L., Bellmunt, J., Bezwoda, W., Gardin, G., Gudgeon, A., Chaudri, H. A., and Hornberger, U. Double-blind trial in postmenopausal (PMP) women with advanced breast cancer (ABC) showing a dose-effect and superiority of 2.5 mg letrozole over megestrol acetate (MA). Proc. Annu. Meet. Am. Soc. Clin. Oncol., 15: A64, 1996.
43. Marty, M., Gershanovich, M., Campos, B., Romieu, G., Lurie, H., Bonaventura, T., Jeffery, M., Buzzi, F., Ludwig, H., Bodrogi, I., Reichardt, P., O'Higgins, N., Chaudri, H. A., Friedrich, P., and Biachoff, M. A. Letrozole, a new potent, selective aromatase inhibitor (AI) superior to aminoglutethimide (AG) in postmenopausal women with advanced breast cancer (ABC) previously treated with antiestrogens. J. Clin. Oncol., 16: 156a, 1997.
44. Bergh, J., Bonneterre, J., Illiger, H. J., Murray, R., Nortier, J., Paridaens, R., Rubens, R. D., Samonigg, H., and Van Zyl, J. Vorozole (Rivizor) versus aminoglutethimide (AG) in the treatment of postmenopausal breast cancer relapsing after tamoxifen. J. Clin. Oncol., 16: 155a, 1997.
45. Goss, P., Wine, E., Tannock, I., Schwartz, I. H., and Kremer, A. B. Vorozole versus Megace in postmenopausal patients with metastatic breast carcinoma who had relapsed following tamoxifen. J. Clin. Oncol., 16: 155a, 1997.
46. Haller, D. G., and Glick, J. H. Progestational agents in advanced breast cancer: an overview. Semin. Oncol., 13 (Suppl. 4):, 2-8, 1986.
47. Sedlacek, S. M. An overview of megestrol acetate for the treatment of advanced breast cancer. Semin. Oncol., 15 (Suppl. 1):, 3-13, 1988.
48. Kettel, L. M. Clinical applications of the antiprogestins. Clin. Obstet. Gynecol., 38: 921-934, 1995.
49. Perrault, D., Eisenhauer, E. A., Pritchard, K. I., Panasci, L., Norris, B., Vandenberg, T., and Fisher, B. Phase II study of the progesterone antagonist mifepristone in patients with untreated metastatic breast carcinoma: a National Cancer Institute of Canada Clinical Trials Group Study. J. Clin. Oncol., 14: 2709-2712, 1996.
50. Kloosterboer, H. J., Deckers, G. H., and Schoonen, W. G. Pharmacology of two new very selective antiprogestagens, ORG 31710 and ORG 31806. Hum. Reprod., 9 (Suppl):, 47-52, 1994.
51. Boccuzzi, G., and Tamagno, E. Growth inhibition of DMBA-induced rat mammary carcinomas by the antiandrogen flutamide. J. Cancer Res. Clin. Oncol., 121: 150-154, 1995.
52. Perrault, D. J., Logan, D. M., Stewart, D. J., Bramwell, V. H., Paterson, A. H., and Eisenhauer, E. A. Phase II study of flutamide in patients with metastatic breast cancer. A National Cancer Institute of Canada Clinical Trials Group study. Invest. New Drugs, 6: 207-210, 1988.
53. Lopez, M., Natali, M., Di Lauro, L., Vici, P., Pignatti, F., and Carpano, S. Combined treatment with buserelin and cyproterone acetate in metastatic male breast cancer. Cancer (Phila.), 72: 502-505, 1993.